Skip to main content
ACR Convergence 2025 Main banner
Final Program


Schedule at a Glance
Legend
Presentation Icons
CME
CME
Non-CME
Non-CME
In Person
In Person
On Demand
On Demand
Live Stream
Live Stream
Active Learning
Active Learning
Choose Rheum
Choose Rheum
Emerging Investigator Awardee
Emerging Investigator Awardee

Poster Session

Pediatric

Poster Session B

Session: (1272–1305) Pediatric Rheumatology – Clinical Poster II

1284: Clinical implications of Antiphospholipid Antibodies and Secondary Antiphospholipid Syndrome in Juvenile-onset Systemic Lupus Erythematosus

Monday, October 27, 2025
10:30 AM - 12:30 PM Central Time
Location: Hall F1

    Abstract Poster Presenter(s)

  • DC

    Daniel Clemente, MD,PhD

    Hospital Niño Jesús
    Madrid, Spain

    Disclosure(s): Eli Lilly: Grant/Research Support (Ongoing); GlaxoSmithKlein(GSK): Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing), Travel grants for courses and conferences (Ongoing); Novartis: Travel grants for courses and conferences (Terminated, November 29, 2024); Sanofi: Grant/Research Support (Ongoing)


Background/Purpose: Antiphospholipid antibodies (aPL) have been associated with organ damage and certain features in juvenile-onset systemic lupus erythematosus (jSLE) patients. We aimed to assess the clinical manifestations of jSLE patients according to the presence of aPL and/or clinical antiphospholipid syndrome (APS).

Methods: Patients from the JULES registry were included. JULES is a Spanish multicenter, hospital-based, retrospective, jSLE registry. Three groups were established: a) SLE without antiphospholipid antibodies (jSLE); b) SLE with antiphospholipid antibodies (jSLE-aPL); c) SLE with secondary antiphospholipid syndrome (jSLE-APS). Clinical manifestations were compared between the 3 groups.

Results: We included 249 patients. 177 patients were classified as jSLE, 50 as jSLE-aPL, and 22 as jSLE-APS. The age of the cases ranged from 5 months to 18 years (mean age 12.65, SD 3.31); 207 patients (83.8%) were female. Regarding cardiovascular risk factors, jSLE-APS patients and jSLE-aPL had higher rates of hypertension and dyslipidemia than those with jSLE (p< 0.001). jSLE-APS patients showed higher rates of neurological manifestations (p< 0.05) and thrombopenia (63% in jSLE-APS, 30% in jSLE-aPL and 21% in jSLE, p< 0.01). The presence of livedo reticularis and Raynaud's syndrome was more frequent in the jSL-aPL group (p< 0.05). There were no differences in pulmonary or cardiac manifestations.

Regarding pharmacological treatment, in addition to antiplatelet and anticoagulant therapy, rituximab was used more frequently at the beginning in the jSLE-APS group (p< 0,05) and intravenous immunoglobulins in both jSLE-aPL y jSLE-APS groups (p< 0,01).

Conclusion: jSLE-APS patients exhibited more severe clinical profiles with higher frequencies of major organ involvement than jSLE-aPL and jSLE patients. Further studies are needed to determine the risk and long-term outcomes of aPL-related events.